Abstract:Mitochondria play a central role in cancer progression and tumor metastasis, and nanomedicines targeting mitochondria have emerged as a promising strategy for tumor therapy. However, mitochondria targeting strategies have not been widely explored in the inhibition of tumor metastasis, and they have disadvantages of complicated preparation, low drug loading, systemic toxicity of the carriers and poor accumulation at tumor sites. Here we firstly developed self-assembled nanodrugs with a high drug loading (similar to 68%) comprised of a berberine derivative (Ber) and doxorubicin (Dox) by a simple nano-precipitation method, which successfully altered the target location of Dox from the nucleus to mitochondria and therefore inhibited the proliferation, invasion and migration of MDA-MB-231 cells by triggering cell apoptosis. The surface of nanodrugs was modified with DSPE-PEG-folic acid (DSPE-PEG-FA) and hyaluronic acid (HA) for precise tumor recognition and enhanced accumulation (HA-FA-BD NDs). Upon arrival at the tumor site with the help of the enhanced permeability and retention (EPR) effect, the partial degradation of HA by hyaluronidase (HAase) at the tumor site allowed the partial exposure of the positively charged FA-BD NDs to the cells, then nanodrugs would accumulate and enter tumor cells by dual binding to both folic acid (FA) and CD-44 receptors. Once internalized into lysosomes, both the HA outer shell and DSPE-PEG-FA of nanodrugs were degraded or decomposed completely to expose positively charged BD NDs. Driven by delocalized lipophilic cations, nanodrugs could escape from lysosomes and reach mitochondria to induce a cascade reaction and finally cell apoptosis, as well as suppressing matrix metalloprotease (MMP)-2 and -9 activities and finally cell migration and invasion. In a xenograft mice model of MDA-MB-231 breast cancer cells, the nanodrugs repaired the defects in Mfn 1/Drp 1 mitochondrial proteins, suppressed the activity of MMP-2 and -9, and significantly inhibited tumor cell proliferation and pulmonary metastasis. Our study showed a promising strategy for the treatment of metastatic breast cancer by targeting mitochondria followed by enhanced apoptosis.

Self-assembly of Fluorescent Dehydroberberine Enhances Mitochondria-Dependent Antitumor Efficacy.

Cover Feature: Self-assembly of Fluorescent Dehydroberberine Enhances Mitochondria-Dependent Antitumor Efficacy (Chem. Eur. J. 39/2018)

Dehydroberberine Analogue Nanoassemblies for Inducing and Self-Reporting Mitochondrial Dysfunction in Tumor Cells

Mitochondrial Targeting Nanodrugs Self-Assembled from 9-O-octadecyl Substituted Berberine Derivative for Cancer Treatment by Inducing Mitochondrial Apoptosis Pathways.

A Self-Assembly Active Nanomodulator Based on Berberine for Photothermal Immunotherapy of Breast Cancer Via Dual Regulation of Immune Suppression.

Self-Assembled Nanomedicine Combining A Berberine Derivative And Doxorubicin For Enhanced Antitumor And Antimetastatic Efficacy Via Mitochondrial Pathways Dagger

Triple stimuli-responsive supramolecular nanoassembly with mitochondrial targetability for chemophotothermal therapy

A Tumor-Mitochondria Dual Targeted Aza-Bodipy-based Nanotheranostic Agent for Multimodal Imaging-Guided Phototherapy

Development of a novel berberine-mediated mitochondria-targeting nano-platform for drug-resistant cancer therapy

Self-Assembled Coumarin Nanoparticle in Aqueous Solution as Selective Mitochondrial-Targeting Drug Delivery System.

Self-Assembly Mitochondria-Targeting Donor–Acceptor Type Theranostic Nanosphere Activates ROS Storm for Multimodal Cancer Therapy

Targeted Mitochondrial Fluorescence Imaging-Guided Tumor Antimetabolic Therapy with the Imprinted Polymer Nanomedicine Capable of Specifically Recognizing Dihydrofolate Reductase

Mitochondria-targeting Nanomedicine Self-Assembled from GSH-responsive Paclitaxel-Ss-berberine Conjugate for Synergetic Cancer Treatment with Enhanced Cytotoxicity.

A Mitochondria-Targeting ROS-activated Nanoprodrug for Self-Augmented Antitumor Oxidation Therapy

Berberine-based self-assembly agents with enhanced synergistic antitumor efficacy

Carbon Quantum Dots with Intrinsic Mitochondrial Targeting Ability for Mitochondria-Based Theranostics.

Rational Construction of a Mitochondrial Targeting, Fluorescent Self-Reporting Drug-Delivery Platform for Combined Enhancement of Endogenous ROS Responsiveness.

Sulfenic Acid-Mediated On-Site-specific Immobilization of Mitochondrial-Targeted NIR Fluorescent Probe for Prolonged Tumor Imaging.

Organelle Targeting Self-Assembled Fluorescent Probe for Anticancer Treatment

Dextran-based Nanodrugs with Mitochondrial Targeting/glutathione Depleting Synergy for Enhanced Photodynamic Therapy

Enhanced porphyrin-based fluorescence imaging-guided photodynamic/photothermal synergistic cancer therapy by mitochondrial targeting